BRD2 and melanoma: Another BETi, I-BET151, triggered the selective inhibition of the NF-κB signaling pathway in melanoma cells, regulating genes involved in inflammation (VEGF, CCL-20) and cell cycle progression (CDK6) and suppressing the production of IL-6 and IL-8 via BRD2 displacement [263].